Evidence map›Paper›PMID 33835379›Full record

ArticleHepatology international2021

A new horizon in risk stratification of hepatocellular carcinoma by integrating vessels that encapsulate tumor clusters and microvascular invasion.

Lianghe Lu, Wei Wei, Chaoyun Huang, Shaohua Li, Chong Zhong, Jiahong Wang, Wushen Yu, Yongfa Zhang, Minshan Chen, Yihong Ling and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Hepatology international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lianghe Lu *Department of Hepatobiliary Oncology of Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Wei Wei *Department of Hepatobiliary Oncology of Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Chaoyun Huang *State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, People's Republic of China.
Shaohua Li *Department of Hepatobiliary Oncology of Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Chong ZhongDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Guangzhou University of Chinese Medicine Guangzhou, Guangzhou, People's Republic of China.
Jiahong WangDepartment of Abdominal Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China.
Wushen YuDepartment of General Surgery, Dongguan People's Hospital, Southern Medical University, Dongguan City, Guangdong Province, People's Republic of China.
Yongfa ZhangDepartment of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Minshan ChenDepartment of Hepatobiliary Oncology of Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Yihong LingState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, People's Republic of China. lingyh@sysucc.org.cn.
Rongping GuoDepartment of Hepatobiliary Oncology of Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. guorp@sysucc.org.cn.ORCID http://orcid.org/0000-0003-2799-3463

Funding

Clinical Trials Project (308 Project) of Sun Yat-sen University Cancer Center No. 308-2015-014Clinical Trials Project (5010 Project) of Sun Yat-sen University No. 5010-2017009National Natural Science Foundation of China No. 81871985the Natural Science Foundation of Guangdong Province No. 2017A030310203
6 · The paper itself

Abstract

backgroundVessels that encapsulate tumor clusters (VETC) is a novel described vascular pattern different from microvascular invasion (MVI) for patients with hepatocellular carcinoma (HCC). The prognostic value of integrating VETC and MVI (VETC-MVI model) in HCC patients after resection remains unclear.

methodsFrom January 2013 to December 2016, 498 HCC patients who underwent curative resection were enrolled from five academic centers and stratified into different groups according to their VETC and MVI statuses. Overall survival (OS), disease-free survival (DFS), and early and late recurrence rates were evaluated.

resultsThe patients were divided into four subgroups: VETC

conclusionsVETC status provides additional discriminative information for patients with either MVI

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsHumansNeoplasm InvasivenessNeoplasm Recurrence, LocalNeovascularization, PathologicPrognosisRetrospective StudiesRisk AssessmentBiomarkerClinical researchHepatocellular carcinomaMicrovascular invasionPrognosisRecurrenceResectionSurvivalVascular patternVessels that encapsulate tumor clusters

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.